



Proteomics International

LABORATORIES LTD

ASX Release
15 November 2019

ASX code: PIQ

Proteomics International raises \$3m in heavily oversubscribed Placement

Highlights:

- Proteomics raises A\$3.0 million via a heavily oversubscribed Placement
- The Placement received strong demand from new and existing institutional, family office, sophisticated and professional investors
- The capital raised will be primarily applied to:
 - securing a specific reimbursement code for PromarkerD in the USA, which will enhance the value of this ground-breaking predictive diagnostic test
 - upgrading of facilities and equipment
 - to accelerate pipeline and new IP projects
- Successful capital raising leaves Proteomics well-funded into CY20 and beyond and importantly gives the Company a strong balance sheet for any potential future licensing/partnering discussions around PromarkerD

Medical technology company Proteomics International Laboratories Ltd (“Proteomics” or “the Company”) (ASX: PIQ) is pleased to advise that it has received firm commitments for a share placement to raise \$3.0 million (before costs) through the issue of 10.8 million shares in the Company (the “Placement”). The Placement was at an issue price of \$0.28 per share, a discount of 13.9% to the 20 day VWAP, and was heavily oversubscribed, supported by institutional, sophisticated and professional investors.

Alto Capital acted as Lead Manager and Adelaide Equity Partners acted as Corporate Advisor to the offer.

Funds raised from the Placement significantly strengthen the Company’s balance sheet, providing capital for a number of key value accretive initiatives:

- Advance the commercialisation of PromarkerD
 - Secure specific reimbursement code for PromarkerD in the USA
 - Immunoassay manufacture & upscaling
 - Further regulatory approvals
- Analytical Services and development of IP
 - Upgrade laboratory instruments (supported by Grant funding)
 - Progress pipeline diagnostics & early stage IP
 - Assess and potentially in-license early stage IP

Proteomics International Managing Director, Dr. Richard Lipscombe said, “We are very pleased with the high level of support received from new and existing investors, including a number of institutions and family offices. Given the Company’s lean operating structure, we are now well capitalised to

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

enter 2020, which is expected to be a transformative year for our Company. The funds will be used to not only advance the commercialisation of PromarkerD, but to upgrade our facilities and accelerate the development of existing and potentially new IP. I take this opportunity to thank existing shareholders for their continued support and to welcome new investors to the Proteomics International register."

The shares under the Placement are expected to be issued on or around 22 November 2019 pursuant to the Company's 15% placement capacity under Listing Rule 7.1.

ENDS

About PromarkerD (www.PromarkerD.com)

The PromarkerD test system assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant. PromarkerD is a simple blood test that uses a unique protein 'fingerprint' to provide an early detection of the onset of disease. In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has received patent protection in multiple jurisdictions including Europe, China, Japan and the USA.

Further information is available through the PromarkerD web portal.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD. The company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

About Alto Capital (www.altocapital.com.au/)

Alto Capital is an independent investment and advisory firm, located in West Perth. Founded in 2004, Alto has a well-established track record of building clients' wealth, successfully listing private companies on the ASX and completing capital raisings for both private and public companies, including start-ups.

As an independent investment firm, our team's advice is unbiased and always in the best interests of our clients. This is why we've formed solid and long-standing relationships with a large network of investors and companies who trust us to deliver strong returns and provide transparency.

Our firm does more than just invest. We identify companies with growth potential and take them to the next stage. We're proud to say we've successfully launched a range of innovative businesses into global markets and helped shape their futures. Our team has extensive experience across a range of sectors including mining and resources, biotechnology, agriculture and healthcare and many others.

About Adelaide Equity Partners (www.adelaideequity.com.au)

Adelaide Equity Partners Limited is a leading independent investment firm based in Adelaide, South Australia, specialising in the provision of corporate advisory and investor relations services to healthcare, natural resources, industrial, technology, agricultural and energy sectors.

Since 2006, Adelaide Equity Partners has led and/or participated in over \$2 billion in capital raisings

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

and over \$2.9 billion in corporate transactions.

For over a decade, Adelaide Equity has sustained market dominance in the independent corporate advisory sector for small-mid cap ASX listed companies. Our truly independent model enables Adelaide Equity to provide uncompromised advice to clients, providing a platform for premium advice and positive outcomes.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
[Corporate Advisor & Investor Relations]
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au

Tony Locantro
[Lead Manager]
Alto Capital
T: +61 8 9223 9888
E: Tony@altocapital.com.au